Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Objective: To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). Methods: This retrospective study included 108 HCC patients with PVTT of the main trunk or first branch and Child-Pugh ≤7. Sixty-eight received HAIC + RT and 40 received sorafenib. Patients were then assigned to the HAIC + RT group ( n = 36) and the sorafenib group ( n = 36) through case-control matching. The decision to treat with HAIC + RT or sorafenib was left to the attending physician. Results: The median overall, progression-free, and postprogression survival were significantly longer in the HAIC + RT group than in the sorafenib group (9.9 vs. 5.3, p = 0.002; 3.9 vs. 2.1, p = 0.048; and 3.7 vs. 1.9 months, p = 0.02, respectively). Multivariate analysis identified HAIC + RT (hazard ratio = 2.02; 95% confidence interval, 1.14–3.57; p = 0.01) as a significant and independent determinant of overall survival. Conclusions: In patients with advanced HCC and major PVTT, survival was significantly longer in those treated with HAIC + RT than with sorafenib.

Related collections

Author and article information

Journal

Journal ID (publisher-id): OCL

Journal ID (nlm-ta): Oncology

Journal ID (doi): 10.1159/issn.0030-2414

Title: Oncology

Publisher: S. Karger AG

ISSN (Print): 0030-2414

ISSN (Electronic): 1423-0232

Publication date Subscription-year: 2018

Publication date (Print): March 2018

Publication date (Electronic): 09 February 2018

Volume: 94

Issue: 4

Pages: 215-222

Affiliations

[_a] _aDepartment of Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University, Hiroshima, Japan

[_b] _bHiroshima City Asa Hospital, Hiroshima, Japan

[_c] _cHiroshima Red Cross Hospital, Hiroshima, Japan

[_d] _dKure Medical Center, Hiroshima, Japan

[_e] _eChugoku Rousai Hospital, Hiroshima, Japan

[_f] _fHiroshima General Hospital, Hiroshima, Japan

[_g] _gDepartment of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan

Author notes

*Dr. Hiroshi Aikata, Department of Medicine and Molecular Science, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551 (Japan), E-Mail aikata@hiroshima-u.ac.jp

Author information

Shinsuke Uchikawa https://orcid.org/0000-0002-1538-4946

Article

Publisher ID: 486483 Other ID: Oncology 2018;94:215–222

DOI: 10.1159/000486483

PubMed ID: 29428943

SO-VID: 031ea373-d6bb-4561-aa54-d86e1fdbf5bf

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 18 October 2017

Date accepted : 19 December 2017

Page count

Figures: 2, Tables: 6, Pages: 8

Comments

Comment on this article

scite_

Cited by 18

See all cited by

Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

Submit here before May 31, 2024